Live Analyst Rating Changes 22588 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mohit Bansal
WF

Mohit Bansal

Wall Street Analyst
★★★☆☆
#1726
on 13Foresight · ranked by our own returns
60%
Success Rate
-0.7%
Average Return
50 of 84 calls profitable · -4.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 60% of Mohit Bansal's ratings turned a profit when each position was held for 2 year — averaging -0.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

123 Buy 54 Hold 0 Sell
Mohit's Stock Coverage 35 ratings · 2026-08-11
Company Date Position Consensus Price Target 2-Yr Return vs S&P 500
BMRN
BioMarin Pharmaceutical
Aug 07, 2026 BUY Strong Buy
+40.8% avg upside
52 analysts
$80.00
16.59% Upside
+9.1% ·
HALO
Halozyme
Aug 07, 2026 HOLD Strong Buy
-36.5% avg upside
20 analysts
$95.00
7.35% Downside
+0.9% ·
TVTX
Travere Therapeutics
Aug 06, 2026 BUY Strong Buy
-8.0% avg upside
22 analysts
$80.00
30.89% Upside
-1.3% ·
LLY
Eli Lilly & Co
Aug 05, 2026 BUY Strong Buy
-14.0% avg upside
48 analysts
$1330.00
8.82% Upside
+4.5% ·
PFE
Pfizer
Aug 05, 2026 HOLD Buy
+24.0% avg upside
45 analysts
$28.00
3.79% Upside
+4.8% ·
MRK
Merck & Company
Aug 05, 2026 BUY Strong Buy
-0.9% avg upside
43 analysts
$150.00
14.95% Upside
+0.2% ·
GILD
Gilead Sciences
Aug 05, 2026 BUY Strong Buy
-10.7% avg upside
66 analysts
$165.00
24.19% Upside
+1.0% ·
VRTX
Vertex Pharmaceuticals
Aug 04, 2026 BUY Strong Buy
-14.3% avg upside
62 analysts
$550.00
4.49% Upside
+3.6% ·
VERA
Vera Therapeutics
Aug 04, 2026 BUY Strong Buy
+122.0% avg upside
19 analysts
$70.00
121.74% Upside
+9.8% ·
AMGN
Amgen
Aug 04, 2026 HOLD Buy
-23.9% avg upside
57 analysts
$400.00
3.34% Downside
+7.0% ·
ABBV
AbbVie
Aug 03, 2026 BUY Strong Buy
-3.4% avg upside
46 analysts
$295.00
20.14% Upside
+2.0% ·
JAZZ
Jazz Pharmaceuticals
Aug 03, 2026 BUY Strong Buy
-7.9% avg upside
35 analysts
$300.00
16.59% Upside
-1.5% ·
NBIX
Neurocrine
Jul 31, 2026 BUY Strong Buy
+14.1% avg upside
37 analysts
$200.00
21.48% Upside
-2.0% ·
REGN
Regeneron
Jul 31, 2026 HOLD Strong Buy
-2.3% avg upside
58 analysts
$750.00
6.75% Downside
+2.9% ·
BMY
Bristol-Myers Squibb
Jul 31, 2026 HOLD Buy
-5.9% avg upside
42 analysts
$65.00
0.00% Downside
-0.7% ·
BIIB
Biogen
Jul 30, 2026 BUY Strong Buy
+21.9% avg upside
52 analysts
$250.00
20.73% Upside
+0.0% ·
SMMT
Summit Therapeutics
Jul 27, 2026 BUY Strong Buy
+96.0% avg upside
27 analysts
$30.00
105.68% Upside
+13.5% ·
BNTX
BioNTech SE
Jul 24, 2026 BUY Strong Buy
+43.6% avg upside
26 analysts
$140.00
50.66% Upside
+3.5% ·
MIST
Milestone Pharmaceuticals
Jul 22, 2026 BUY Strong Buy
+552.0% avg upside
7 analysts
$7.00
457.82% Upside
+0.8% ·
IRWD
Ironwood Pharma
May 05, 2026 HOLD Buy
+189.3% avg upside
23 analysts
$5.00
22.65% Upside
-7.5% ·
WVE
Wave Life Sciences
Apr 01, 2026 BUY Strong Buy
+246.2% avg upside
28 analysts
$13.00
115.71% Upside
-10.7% ·
MLYS
Mineralys Therapeutics, Inc.
Mar 13, 2026 BUY Strong Buy
+64.8% avg upside
12 analysts
$55.00
102.80% Upside
+3.6% ·
XENE
Xenon
Aug 12, 2025 BUY Strong Buy
-2.7% avg upside
28 analysts
$47.00
25.86% Downside
+78.0% ·
ARWR
Arrowhead Pharmaceuticals
Jul 02, 2021 BUY Strong Buy
-14.8% avg upside
27 analysts
$95.00
7.88% Upside
-43.5% ·
FTH
Faeth Therapeutics
Jun 29, 2021 BUY Strong Buy
+63.1% avg upside
16 analysts
$14.00
51.58% Downside
-85.3% ·
NMTRQ
9 Meters Biopharma
Jun 04, 2021 BUY Buy
+3234374900.0% avg upside
11 analysts
$3.00
299999899.95% Upside
· ·
PLRX
Pliant Therapeutics
Apr 05, 2021 BUY Buy
+2032.1% avg upside
21 analysts
$52.00
4852.46% Upside
· ·
FBRX
Forte Biosciences
Mar 26, 2021 BUY Buy
-35.4% avg upside
15 analysts
$75.00
2.33% Downside
· ·
IDYA
IDEAYA Biosciences
Mar 24, 2021 BUY Strong Buy
+32.1% avg upside
29 analysts
$33.00
9.84% Downside
-35.0% ·
CHRS
Coherus Biosciences
Feb 25, 2021 BUY Buy
+878.4% avg upside
18 analysts
$27.00
2001.27% Upside
-54.5% ·
STTK
Shattuck Labs
Jan 20, 2021 BUY Strong Buy
+204.8% avg upside
15 analysts
$75.00
943.03% Upside
-94.2% ·
AGIO
Agios Pharma
Dec 23, 2020 BUY Strong Buy
+87.6% avg upside
29 analysts
$65.00
100.36% Upside
-38.3% ·
CTMX
CytomX Therapeutics
Sep 15, 2020 HOLD Strong Buy
+217.3% avg upside
21 analysts
$8.50
150.44% Upside
-77.0% ·
ADAPY
Adaptimmune Therapeutics
Apr 27, 2020 BUY Buy
+7723.8% avg upside
10 analysts
$5.00
16566.74% Upside
· ·
AVTR
Avantor
Jun 11, 2019 BUY Buy
+13.0% avg upside
26 analysts
$21.00
53.44% Upside
+89.9% ·
🔒 30 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Mohit Bansal — Frequently Asked Questions
How accurate are Mohit Bansal's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Mohit's ratings were profitable over a one-year hold, with an average return of -0.9% per rating, or -4.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Mohit ranked on 13Foresight?
Mohit Bansal is currently ranked #1726 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mohit cover?
Mohit most recently has ratings on BMRN, HALO, TVTX, LLY, PFE, MRK, GILD, VRTX, VERA, AMGN, ABBV, JAZZ and 23 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.